Sertraline

Generic Name: Sertraline

Brand Names: Zoloft

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₇Cl_₂N

CAS Number: 79617-96-2

Unique Ingredient Identifier: QUC7NX6WMB

Background: Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as Citalopram and Fluoxetine. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects.

Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.

Indication: Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD). Common off-label uses for sertraline include the prevention of post stroke depression, generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.

Associated Conditions: Binge Eating Disorder (BED), Bulimia Nervosa, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD)

Associated Therapies: -

Clinical Trials

Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy

Phase 3

Completed

Conditions: Bipolar Disorder
Bipolar Depression

Interventions: Drug: Extended release quetiapine (quetiapine XR)
Drug: Sertraline
Drug: adequate mood stabilizer

First Posted Date: 2009-03-06

Last Posted Date: 2012-04-18

Lead Sponsor: AstraZeneca

Target Recruit Count: 27

Registration Number: NCT00857584

Locations: 🇪🇸
Research Site, Vitoria, Pais Vasco, Spain

Treatment Trial for Psychogenic Nonepileptic Seizures

Phase 4

Completed

Conditions: Dissociative Disorders
Stress Disorders, Post-Traumatic
Conversion Disorder
Depression
Convulsion, Non-Epileptic

Interventions: Drug: sertraline
Other: Standard Care
Behavioral: CBT-ip
Other: Combined (sertraline + CBT-ip)

First Posted Date: 2009-02-03

Last Posted Date: 2014-11-10

Lead Sponsor: Rhode Island Hospital

Target Recruit Count: 38

Registration Number: NCT00835627

Locations: 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
Rhode Island Hospital, Providence, Rhode Island, United States

Adding an Insulin-Sensitizing Medication to Depression Treatment for People Who Are Depressed and Overweight

Phase 4

Completed

Conditions: Depression

Interventions: Drug: Sertraline
Drug: Metformin

First Posted Date: 2009-02-03

Last Posted Date: 2018-09-10

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 206

Registration Number: NCT00834652

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Postpartum Depression: Transdermal Estradiol Versus Sertraline

Phase 4

Terminated

Conditions: Postpartum Depression

Interventions: Drug: Transdermal Estradiol
Drug: Sertraline
Other: Placebo

First Posted Date: 2008-08-29

Last Posted Date: 2019-09-10

Lead Sponsor: Northwestern University

Target Recruit Count: 85

Registration Number: NCT00744328

Locations: 🇺🇸
Northwestern University Feinberg School of Medicine; Asher Center for the Study and Treatment of Depressive Disorders, Chicago, Illinois, United States

Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury

Phase 2

Completed

Conditions: Traumatic Brain Injury

Interventions: Drug: Placebo
Drug: Sertraline

First Posted Date: 2008-06-24

Last Posted Date: 2015-08-25

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 94

Registration Number: NCT00704379

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States

International Study to Predict Optimised Treatment - in Depression

Phase 4

Conditions: Major Depressive Disorder

Interventions: Drug: Venlafaxine-XR
Drug: Escitalopram
Drug: Sertraline

First Posted Date: 2008-06-09

Last Posted Date: 2018-07-11

Lead Sponsor: BRC Operations Pty. Ltd.

Target Recruit Count: 2688

Registration Number: NCT00693849

Locations: 🇺🇸
Shanti Clinical Trials, Colton, California, United States
🇺🇸
A.D.D. Treatment Center, Mission Viejo, California, United States
🇺🇸
Veteran Affairs/Stanford University, Stanford, California, United States

and more 16 locations

A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder

Phase 4

Completed

Conditions: Panic Disorder

Interventions: Drug: Paroxetine
Drug: sertraline

First Posted Date: 2008-05-14

Last Posted Date: 2021-01-27

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 321

Registration Number: NCT00677352

Locations: 🇯🇵
Pfizer Investigational Site, Minato-ku, Japan

A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression

Phase 4

Completed

Conditions: Depression

Interventions: Drug: duloxetine
Drug: citalopram
Drug: fluoxetine
Drug: sertraline
Drug: paroxetine

First Posted Date: 2008-04-25

Last Posted Date: 2010-06-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 750

Registration Number: NCT00666757

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brown Deer, Wisconsin, United States